【摘要】：近年新型抗青光眼藥物——固定聯(lián)合制劑陸續(xù)在我國上市。固定聯(lián)合制劑是由兩種或兩種以上不同降眼壓機制的青光眼藥物聯(lián)合組成,降壓效果強于單制劑或不劣于它們協(xié)同使用。固定聯(lián)合制劑仍然存在與單制劑類似的副作用,但少于單制劑。固定聯(lián)合制劑為臨床上使用兩種以上藥物降眼壓患者提供更有力的降壓效果,提高治療方案的便利性,減少多瓶用藥防腐劑對眼表的損害,改善病人的依從性和藥物治療的持久性。
[Abstract]:In recent years, new antiglaucoma drugs-fixed combination preparations have been listed in China. Fixed combination is composed of two or more glaucoma drugs with different mechanisms of reducing intraocular pressure, and the antihypertensive effect is stronger than or no worse than that of single preparation or their combination. Fixed combination preparations still have similar side effects to single preparations, but less than single preparations. The combination of fixed preparation provides more powerful antihypertensive effect for patients with more than two kinds of drugs in clinical use, improves the convenience of treatment, reduces the damage to eye surface caused by multiple bottles of preservatives, and improves the compliance of patients and the persistence of drug therapy.
【作者單位】： 第三軍醫(yī)大學野戰(zhàn)外科研究所大坪醫(yī)院眼科;
【分類號】：R988.1

【相似文獻】

相關(guān)期刊論文 前2條

1 朱明理;淺談聯(lián)合制劑室的監(jiān)督管理[J];中國藥事;1990年02期

2 ;[J];;年期

，

本文編號：2502280